Trials / Completed
CompletedNCT03802162
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-355.
Detailed description
An open-label, randomized, multiple-dosing parallel study to evaluate the pharmacokinetics, safety and tolerability of CKD-355 with D797 and D324 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-355A (D797/Memantine HCl 20mg) | once a day |
| DRUG | CKD-355B (D797/Memantine HCl 20mg) | once a day |
| DRUG | D797 | once a day |
| DRUG | D324 (Memantine HCl 10mg) | twice a day |
Timeline
- Start date
- 2019-02-15
- Primary completion
- 2019-05-10
- Completion
- 2019-08-31
- First posted
- 2019-01-14
- Last updated
- 2019-10-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03802162. Inclusion in this directory is not an endorsement.